Independent NDC12 resource · Not affiliated with the FDA
Regulatory facts linked to current FDA sources View FDA source
The transition to a 12-digit NDC is entering a new phase. Industry attention is moving beyond the rule itself and toward implementation. As organizations begin to align, areas of friction will start to emerge.
The FDA has issued the final rule revising the 12-digit National Drug Code (NDC12) format. This confirms the format and establishes a date for implementation.
On March 10, 2026 - the NDC12 conversation moves from awareness to execution at the HDA Distribution Management Conference (DMC). Follow this blog for an overview of the session and a final recap once it's completed.
Waiting on NDC12 is no longer neutral. The FDA failed to issue the final rule on NDC12. Some see this as a reason to wait. That is the wrong move.
The FDA has missed its date to publish the final rule for NDC12. This heightens the risk for the industry. This article explores one option the FDA can use to extend the deadline, but it carries consequences we must understand.
Most organizations don’t know where NDC12 will break them. The NDC12 Readiness Assessment is a simple tool to surface risk, start the right conversations, and bring clarity to what readiness really means.
The industry has known NDC12 was coming since 2018, yet the Final Rule remains trapped in a bureaucratic loop. Every month spent 'reviewing' is a month stolen from your implementation window. We need to stop 'waiting and seeing' and demand a date. Eric Marshall and the team at Leavitt Partners have initiated a push to expedite this; read more to see how you can join the effort.
